King's College London

Research portal

Deconstructing Depression and negative symptoms of Schizophrenia; differential and longitudinal immune correlates, and response to Minocycline treatment

Research output: Contribution to journalArticlepeer-review

Carl Krynicki, Paola Dazzan, Carmine Pariante, Nicholas Barnes, Rachel C Vincent, Alex Roberts, Annalisa Giordano, Andrew Watson, John Suckling, Thomas R. E. Barnes, Nusrat Husain, Peter B. Jones, Eileen M. Joyce, Stephen M. Lawrie, Shôn Lewis, Bill Deakin, Rachel Upthegrove

Original languageEnglish
Article numberBBI_2020_1032R2  
Number of pages28
JournalBrain Behavior and Immunity
Accepted/In press31 Oct 2020


  • BBI paper v.3 - clean

    BBI_paper_v.3_clean.docx, 332 KB, application/vnd.openxmlformats-officedocument.wordprocessingml.document

    Uploaded date:12 Nov 2020

King's Authors


Background: Immune dysfunction has been implicated in negative symptoms of schizophrenia and also in depression. These disorders are frequently co-morbid, with some symptoms such as anhedonia and apathy common to both. The anti-inflammatory agent minocycline may be ineffective in schizophrenia, but more positive effects have been seen in depression. Our aim was to investigate the role of immune dysfunction in depression and sub-domains of negative symptoms in schizophrenia by investigating their intercorrelation and the influence of treatment with minocycline. Methods: We analysed longitudinal data from 207 patients within 5 years of onset of schizophrenia, from the randomised double-blind, placebo-controlled trial of minocycline (BeneMin). Symptom ratings and circulating IL-6, C-reactive protein (CRP) and TNF-α concentrations were collected at baseline and repeated over twelve months. The sample was not stratified by CRP prior to randomisation. Positive and Negative Syndrome Scale composite ratings of avolition-apathy and diminished expression, Calgary Depression Scale total scores, and immune markers were examined cross-sectionally using Spearman’s rank, and longitudinally by linear mixed effect models that included body mass index and minocycline. Additionally, post hoc analysis of the sample stratified by elevated CRP (>1 mg/l and <10 mg/l at baseline) was carried out to assess whether minocycline had any effect on specific symptoms in an immune active sub-group of patients. Results: Depression and avolition-apathy were significantly positively related, and depression correlated weakly with IL-6 at baseline. Diminished expression was associated with increased TNF-α both cross-sectionally and longitudinally. CRP was unrelated to any symptom domain. Minocycline did not affect any individual symptom or sub-domain in the full sample or in the immune active sub-group. Discussion: IL-6 may have some specificity to depression in early schizophrenia. TNF-α may be an indicator of immune dysfunction relevant to negative symptoms, and our longitudinal findings add to this evidence. However, minocycline continues to show very little promise as a treatment for any symptom dimension of early schizophrenia. Key words: Depression, negative symptoms, inflammation, cytokines, minocycline.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454